Page 1

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30 , 2021 August 9 , 2021 Reports Net Revenues of $ 101.7 Million for the Three Months Ended June 30 , 2021 RANCHO CUCAMONGA , CA / ACCESSWIRE / August 9 , 2021 / Amphastar Pharmaceuticals , Inc. ( NASDAQ : AMPH ) ( " Amphastar " or the " Company " ) today reported results for the three months ended June 30 , 2021 . Second Quarter Highlights • Net revenues of $ 101.7 million for the second quarter • GAAP net income of $ 7.8 million , or $ 0.16 per share , for the second quarter • Adjusted non - GAAP net income of $ 10.6 million , or $ 0.21 per share , for the second quarter Dr. Jack Zhang , Amphastar's President and Chief Executive Officer , commented : " Continued strong sales of glucagon , Primatene Mist® and our epinephrine products led to another strong quarter of growth . We believe that these products will continue to drive growth as we continue to develop and realize approvals from our pipeline . " Three Months Ended June 30 , Six Months Ended June 30 , 2021 2020 2021 2020 Net revenues GAAP net income ( loss ) attributable to Amphastar ( in thousands , except per share data ) $ 101,663 $ 85,806 $ 204,683 $ 170,494 $ 7,767 $ ( 192 ) $ 12,808 $ 3,757 Adjusted non - GAAP net income attributable to Amphastar * $ 10,615 $ 7,610 $ 24,168 $ 15,993 GAAP diluted EPS attributable to Amphastar stockholders $ 0.16 $ ( 0.00 ) $ 0.26 $ 0.08 Adjusted non - GAAP diluted EPS attributable to Amphastar stockholders * $ 0.21 $ 0.16 $ 0.49 $ 0.33 * Adjusted non - GAAP net income attributable to Amphastar and Adjusted non - GAAP diluted EPS attributable to Amphastar stockholders are non - GAAP financial measures . Please see the discussion in the section entitled " Non - GAAP Financial Measures " and the reconciliation of GAAP to non- GAAP financial measures in Table III of this press release . Second Quarter Results